Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Eli Lilly & Company has increased the price of Mounjaro in the UK by 170% to make it cheaper in the US, while Google has issued a cybersecurity warning to its 1.8 billion Gmail users, and the FDA has ...

Former Uber regional manager and Oscar Health COO has set out on her own to help busy people get help with their schedules by ...

The Global Women’s Health Market is expected to witness a growth rate of 4-5% in the next five years. Growing incidence of ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...